Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | PHASE1 | COMPLETED | 13 | — | — | Nov 1, 2013 | Mar 1, 2017 | Aug 17, 2017 | 4 | United States |
To evaluate the safety and tolerability of multiple ascending doses of intramuscular (IM) IDC-G305
| Arm | Type | Description |
|---|---|---|
| IDC-G305 | EXPERIMENTAL | NY-ESO-1 recombinant protein together with GLA-SE |
| Name | Type | Description |
|---|---|---|
| IDC-G305 | BIOLOGICAL | NY-ESO-1 recombinant protein together with GLA-SE |
Inclusion Criteria: * Confirmed diagnosis of melanoma, ovarian cancer, sarcoma, breast cancer or non-small cell lung cancer (NSCLC) * Unresectable, relapsed and/or metastatic cancer with minimal or low disease burden. Disease may or may not be measurable and should not be rapidly progressive. Inade...